Learn more about our novel target for treatment of chronic inflammatory diseases. We will attend: BIO-Europe in Berlin, Nov 6-8 Nordic-American conference in New York, Nov 13-14 RESI meeting in New York, Nov 15 We will tell you more about Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody. Lipum has collected [...]
Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén at BIO-Europe 2017 in Berlin, Nov 6-8. We will tell you more on our novel target Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody for treatment of these diseases. Lipum has collected original research data [...]
We invite investors to join us in the development towards better treatment of chronic inflammations. Meet us and learn more at the 17th Annual Biotech in Europe Forum, Basel, Sept 26-27.
Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén at Nordic Life Science Days 2017 in Malmö. A novel target molecule We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and [...]
Rheumatism is an autoimmune disease that causes chronic inflammation and pain. The inflammation can break down cartilage, adjacent bones, tendons and arteries. Also eyes and other organs can be affected. About one percent of the population suffer of the disease. It is more common among women than men. Drug market for the disease is estimated to [...]
Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén at the NLSDays 2017. We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and our ongoing development of a therapeutic antibody [...]
Lipum AB is the assignee of a strong patent portfolio and the rights of the patent from the inventors and the results within the BSSL research have all been transferred to the company. The patent "New method for treatment of inflammatory diseases.", previously granted on most major markets, has now also been approved in Canada. [...]
We will present our recent advancements in the development of a biological drug for treatment of chronic inflammatory diseases. Pre-clinical results based on well established models have shown the importance of our novel target molecule, the bile-salt stimulated lipase (BSSL). The development of a humanised antibody is in progress and Lipum is actively seeking partners [...]
Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén or Chairman Ulf Björklund at BIO-Europe Spring 2017 in Barcelona. We will tell you more on our novel target bile salt-stimulated lipase (BSSL) and our ongoing development [...]
Meet Lipum at Sachs Associates 10th Annual ELSCEO Forum & Exhibition, on 6-7th March 2017 at the Hilton Zürich Airport Hotel, Switzerland. This event bring together a cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders. Please contact us to book a meeting on March 6-7, 2017.